Clinicopathological differences between variants of the NAB2–STAT6 fusion gene in solitary fibrous tumors of the meninges and extra-central nervous system

详细信息    查看全文

• 作者：Satoko Nakada ; Hiroshi Minato ; Takayuki Nojima
• 刊名：Brain Tumor Pathology
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：33
• 期：3
• 页码：169-174
• 全文大小：1,110 KB
• 刊物主题：Neurosurgery; Neurology; Pathology; Oncology; Cancer Research;
• 出版者：Springer Japan
• ISSN：1861-387X
• 卷排序：33

文摘

Investigations on the NAB2–STAT6 fusion gene in solitary fibrous tumors (SFTs) and hemangiopericytomas (HPCs) have increased since its discovery in 2013. Although several SFTs reported without NAB2–STAT6 fusion gene analysis, we reviewed 546 SFTs/HPCs with NAB2–STAT6 fusion gene analysis in this study and investigated differences between the gene variants. In total, 452 cases tested positive for the NAB2–STAT6 fusion gene, with more than 40 variants being detected. The most frequent of these were NAB2 exon 6-STAT6 exon 16/17/18 and NAB2 exon 4-STAT6 exon 2/3, with the former occurring most frequently in SFTs in meninges, soft tissues, and head and neck; the latter predominated in SFTs in the pleura and lung. There was no difference between the histology of SFTs and fusion gene variants. A follow-up analysis of SFTs showed that 51 of 202 cases had a recurrence, with 18 of 53 meningeal SFTs having a local recurrence and/or metastasis within 0–19 years. In meninges and soft tissue, SFTs with the NAB2 exon 6-STAT6 exon 16/17/18 tended to recur more frequently than SFTs with the NAB2 exon 4-STAT6 exon 2/3. Clinicopathological data, including yearly follow-ups, are required for meningeal SFTs/HPCs to define the correlation of variants of NAB2–STAT6 fusion gene.KeywordsSolitary fibrous tumorHemangiopericytomaMeningesNAB2–STAT6 fusion gene